 Catalyst Biosciences Inc NASDAQ: CBIO has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated NASDAQ: VRTX for 60 million. This sale is part of the ongoing strategic process that we announced in. 